Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver.

Hegde P, Weiss E, Paradis V, Wan J, Mabire M, Sukriti S, Rautou PE, Albuquerque M, Picq O, Gupta AC, Ferrere G, Gilgenkrantz H, Kiaf B, Toubal A, Beaudoin L, Lettéron P, Moreau R, Lehuen A, Lotersztajn S.

Nat Commun. 2018 Jun 1;9(1):2146. doi: 10.1038/s41467-018-04450-y.

2.

Acute-on-chronic liver failure 2018: a need for (urgent) liver biopsy?

van Leeuwen DJ, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell L, Gill RM, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Rautou PE, Sempoux C, Snover DC, Theise ND, Thung SN, Tsui WMS, Quaglia A, Liver Pathology Study Group TI.

Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):565-573. doi: 10.1080/17474124.2018.1481388. Epub 2018 Jun 14.

PMID:
29806950
3.

Hepatocellular nodules in vascular liver diseases.

Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P.

Virchows Arch. 2018 Jul;473(1):33-44. doi: 10.1007/s00428-018-2373-6. Epub 2018 May 26. Review.

PMID:
29804132
4.

Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.

Bienaimé F, Ambolet A, Aussilhou B, Brazier F, Fouchard M, Viau A, Barre P, Tissier AM, Correas JM, Paradis V, Terzi F, Friedlander G, Knebelmann B, Joly D, Prié D.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2319-2328. doi: 10.1210/jc.2018-00123.

PMID:
29618028
5.

Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.

Payancé A, Silva-Junior G, Bissonnette J, Tanguy M, Pasquet B, Levi C, Roux O, Nekachtali O, Baiges A, Hernández-Gea V, Laouénan C, Lebrec D, Albuquerque M, Paradis V, Moreau R, Valla D, Durand F, Boulanger CM, Garcia-Pagan JC, Rautou PE.

Hepatology. 2018 Mar 30. doi: 10.1002/hep.29903. [Epub ahead of print]

PMID:
29603327
6.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Mar 24. doi: 10.1002/hep.29884. [Epub ahead of print]

PMID:
29572896
7.

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.

Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc'h K, Manceau H, Gouya L.

J Intern Med. 2018 Jul;284(1):78-91. doi: 10.1111/joim.12750. Epub 2018 Mar 26.

PMID:
29498764
8.

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T.

Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.

9.

Benign and malignant hepatocellular lesions in patients with vascular liver diseases.

Vilgrain V, Paradis V, Van Wettere M, Valla D, Ronot M, Rautou PE.

Abdom Radiol (NY). 2018 Aug;43(8):1968-1977. doi: 10.1007/s00261-018-1502-7.

PMID:
29460040
10.

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N.

Hepatology. 2018 Jul;68(1):113-126. doi: 10.1002/hep.29789. Epub 2018 May 9.

PMID:
29360137
11.

Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.

Ziol M, Poté N, Amaddeo G, Laurent A, Nault JC, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-Rossi J, Barget N, Seror O, Ganne-Carrié N, Paradis V, Calderaro J.

Hepatology. 2018 Jul;68(1):103-112. doi: 10.1002/hep.29762. Epub 2018 May 9.

PMID:
29281854
12.

Noninvasive assessment of liver steatosis in deceased donors: A pilot study.

Cesaretti M, Poté N, Cauchy F, Dondero F, Dokmak S, Sepulveda A, Schneck AS, Francoz C, Durand F, Paradis V, Soubrane O.

Liver Transpl. 2018 Apr;24(4):551-556. doi: 10.1002/lt.25002. No abstract available.

PMID:
29272077
13.

Volumetric measurement of hepatic tumors: Accuracy of manual contouring using CT with volumetric pathology as the reference method.

Pupulim LF, Ronot M, Paradis V, Chemouny S, Vilgrain V.

Diagn Interv Imaging. 2018 Feb;99(2):83-89. doi: 10.1016/j.diii.2017.11.002. Epub 2017 Dec 6.

PMID:
29221936
14.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

PMID:
29150490
15.

Cystic fibrosis liver disease in adults: Limits of noninvasive tests of fibrosis.

Hillaire S, Cazals-Hatem D, Erlinger S, Paradis V.

Hepatology. 2017 Nov 3. doi: 10.1002/hep.29637. [Epub ahead of print] No abstract available.

PMID:
29105109
16.

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.

Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J.

Nat Commun. 2017 Nov 3;8(1):1315. doi: 10.1038/s41467-017-01358-x.

17.

Testing feasibility of an accurate microscopic assessment of macrovesicular steatosis in liver allograft biopsies by smartphone add-on lenses.

Cesaretti M, Poté N, Dondero F, Cauchy F, Schneck AS, Soubrane O, Paradis V, Diaspro A, Antonini A.

Microsc Res Tech. 2018 Jan;81(1):58-63. doi: 10.1002/jemt.22956. Epub 2017 Oct 17.

PMID:
29044859
18.

Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences.

Barbier L, Ronot M, Aussilhou B, Cauchy F, Francoz C, Vilgrain V, Soubrane O, Paradis V, Belghiti J.

Hepatology. 2017 Oct 10. doi: 10.1002/hep.29582. [Epub ahead of print]

PMID:
29023812
19.

Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study.

Poté N, Cauchy F, Albuquerque M, Cros J, Soubrane O, Bedossa P, Paradis V.

Liver Int. 2018 Apr;38(4):687-694. doi: 10.1111/liv.13585. Epub 2017 Sep 24.

PMID:
28872754
20.

Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy.

Hillaire S, Cazals-Hatem D, Bruno O, de Miranda S, Grenet D, Poté N, Soubrane O, Erlinger S, Lacaille F, Mellot F, Vilgrain V, Paradis V.

Liver Transpl. 2017 Oct;23(10):1342-1347. doi: 10.1002/lt.24842. No abstract available.

PMID:
28816015
21.

Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition.

Cazals-Hatem D, Billiauws L, Rautou PE, Bondjemah V, Poté N, Corcos O, Paradis V, Joly F.

Liver Int. 2018 Jan;38(1):174-182. doi: 10.1111/liv.13545. Epub 2017 Sep 2.

PMID:
28792647
22.

Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness.

Sharma S, Maras JS, Das S, Hussain S, Mishra AK, Shasthry SM, Sharma CB, Weiss E, Elkrief L, Rautou PE, Gilgenkrantz H, Lotersztajn S, Paradis V, de la Grange P, Junot C, Moreau R, Sarin SK.

Sci Rep. 2017 Jul 28;7(1):6816. doi: 10.1038/s41598-017-07161-4.

23.

Molecular classification of hepatocellular adenoma in clinical practice.

Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J.

J Hepatol. 2017 Nov;67(5):1074-1083. doi: 10.1016/j.jhep.2017.07.009. Epub 2017 Jul 19. Review.

PMID:
28733222
24.

Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy.

de Lédinghen V, Hiriart JB, Vergniol J, Merrouche W, Bedossa P, Paradis V.

Dig Dis Sci. 2017 Sep;62(9):2569-2577. doi: 10.1007/s10620-017-4638-3. Epub 2017 Jun 2.

PMID:
28577247
25.

Tri-directional anaphases as a novel chromosome segregation defect in human oocytes.

Haverfield J, Dean NL, Nöel D, Rémillard-Labrosse G, Paradis V, Kadoch IJ, FitzHarris G.

Hum Reprod. 2017 Jun 1;32(6):1293-1303. doi: 10.1093/humrep/dex083.

26.

Variant differentiation patterns in primary liver carcinoma.

Sempoux C, Paradis V, Saxena R.

Semin Diagn Pathol. 2017 Mar;34(2):176-182. doi: 10.1053/j.semdp.2017.02.001. Epub 2017 Feb 8.

PMID:
28256363
27.

Fibrosis in Chronic Hepatitis C: Correlation between Immunohistochemically-Assessed Virus Load with Steatosis and Cellular Iron Content.

Akl M, Hindawi AE, Mosaad M, Montasser A, Ray AE, Khalil H, Anas A, Atta R, Paradis V, Hadi AA, Hammam O.

Open Access Maced J Med Sci. 2016 Dec 15;4(4):578-584. doi: 10.3889/oamjms.2016.122. Epub 2016 Nov 15.

28.

IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans.

Alzaid F, Lagadec F, Albuquerque M, Ballaire R, Orliaguet L, Hainault I, Blugeon C, Lemoine S, Lehuen A, Saliba DG, Udalova IA, Paradis V, Foufelle F, Venteclef N.

JCI Insight. 2016 Dec 8;1(20):e88689.

29.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

PMID:
27939373
30.

Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.

Wu Z, Galmiche A, Liu J, Stadler N, Wendum D, Segal-Bendirdjian E, Paradis V, Forgez P.

Cancer Lett. 2017 Mar 1;388:73-84. doi: 10.1016/j.canlet.2016.11.032. Epub 2016 Dec 1.

PMID:
27914862
31.

Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.

Bedossa P, Tordjman J, Aron-Wisnewsky J, Poitou C, Oppert JM, Torcivia A, Bouillot JL, Paradis V, Ratziu V, Clément K.

Gut. 2017 Sep;66(9):1688-1696. doi: 10.1136/gutjnl-2016-312238. Epub 2016 Nov 24. Review.

PMID:
27884920
32.

Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.

de Vries EM, de Krijger M, Färkkilä M, Arola J, Schirmacher P, Gotthardt D, Goeppert B, Trivedi PJ, Hirschfield GM, Ytting H, Vainer B, Buuren HR, Biermann K, Harms MH, Chazouilleres O, Wendum D, Kemgang AD, Chapman RW, Wang LM, Williamson KD, Gouw AS, Paradis V, Sempoux C, Beuers U, Hübscher SG, Verheij J, Ponsioen CY.

Hepatology. 2017 Mar;65(3):907-919. doi: 10.1002/hep.28963. Epub 2017 Jan 11.

PMID:
27880989
33.

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.

Cauchy F, Mebarki M, Leporq B, Laouirem S, Albuquerque M, Lambert S, Bourgoin P, Soubrane O, Van Beers BE, Faivre S, Bedossa P, Paradis V.

Clin Sci (Lond). 2017 Jan 1;131(1):27-36. Epub 2016 Nov 1.

PMID:
27803295
34.

Hepatic Fibrosis, Inflammation, and Steatosis: Influence on the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease.

Leitão HS, Doblas S, Garteiser P, d'Assignies G, Paradis V, Mouri F, Geraldes CF, Ronot M, Van Beers BE.

Radiology. 2017 Apr;283(1):98-107. doi: 10.1148/radiol.2016151570. Epub 2016 Oct 27.

PMID:
27788034
35.

Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.

Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.

Liver Transpl. 2016 Nov;22(11):1491-1500. doi: 10.1002/lt.24615.

36.

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L.

J Hepatol. 2017 Feb;66(2):424-441. doi: 10.1016/j.jhep.2016.09.010. Epub 2016 Sep 26. Review.

PMID:
27686679
37.

Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden.

Ronot M, Cauchy F, Gregoli B, Breguet R, Allaham W, Paradis V, Soubrane O, Vilgrain V.

HPB (Oxford). 2016 Aug;18(8):684-90. doi: 10.1016/j.hpb.2016.05.012. Epub 2016 Jun 18.

38.

Development of Collateral Pathways in Tumor Obstruction of Confluence of the Hepatic Veins: Neither Fortuitous nor Innocuous.

Barbier L, Ronot M, Monsinjon M, Paradis V, Soubrane O, Vilgrain V, Belghiti J.

J Am Coll Surg. 2016 Oct;223(4):595-601. doi: 10.1016/j.jamcollsurg.2016.06.013. Epub 2016 Jun 29.

PMID:
27374994
39.

MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.

Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.

40.

Diabetes mellitus in patients with cirrhosis: clinical implications and management.

Elkrief L, Rautou PE, Sarin S, Valla D, Paradis V, Moreau R.

Liver Int. 2016 Jul;36(7):936-48. doi: 10.1111/liv.13115. Epub 2016 Apr 4. Review.

PMID:
26972930
41.

Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.

Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-Sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WM, van Leeuwen DJ; International Liver Pathology Study Group.

Histopathology. 2016 Jun;68(7):953-67. doi: 10.1111/his.12957. Epub 2016 Apr 28. Review.

PMID:
26918878
42.

Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.

Guedj N, Vaquero J, Clapéron A, Mergey M, Chrétien Y, Paradis V, Fouassier L.

Histopathology. 2016 Aug;69(2):211-21. doi: 10.1111/his.12931. Epub 2016 Mar 1.

PMID:
26791814
43.

When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies.

Tribillon E, Barbier L, Goumard C, Irtan S, Perdigao-Cotta F, Durand F, Paradis V, Belghiti J, Scatton O, Soubrane O.

J Gastrointest Surg. 2016 Jan;20(1):66-76; discussion 76. doi: 10.1007/s11605-015-3018-6. Epub 2015 Nov 18.

PMID:
26582597
44.

Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection.

d'Assignies G, Fayard C, Leitao H, Alfaiate T, Tubach F, Dokmak S, Paradis V, Van Beers BE, Ronot M, Vilgrain V.

Surgery. 2016 Apr;159(4):1050-7. doi: 10.1016/j.surg.2015.10.008. Epub 2015 Nov 12.

PMID:
26582502
45.

Hepatic fat fraction and visceral adipose tissue fatty acid composition in mice: Quantification with 7.0T MRI.

Leporq B, Lambert SA, Ronot M, Boucenna I, Colinart P, Cauchy F, Vilgrain V, Paradis V, Van Beers BE.

Magn Reson Med. 2016 Aug;76(2):510-8. doi: 10.1002/mrm.25895. Epub 2015 Nov 3.

PMID:
26527483
46.

Hepatocellular carcinoma protein carbonylation in virus C and metabolic syndrome patients.

Martin FA, Mebarki M, Paradis V, Friguet B, Radman M.

Free Radic Biol Med. 2014 Oct;75 Suppl 1:S40. doi: 10.1016/j.freeradbiomed.2014.10.789. Epub 2014 Dec 10.

PMID:
26461368
47.

Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression.

Loyer X, Paradis V, Hénique C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, Paul JL, Rothenberg ME, Marcellin P, Durand F, Bedossa P, Prip-Buus C, Baugé E, Staels B, Boulanger CM, Tedgui A, Rautou PE.

Gut. 2016 Nov;65(11):1882-1894. doi: 10.1136/gutjnl-2014-308883. Epub 2015 Sep 3.

48.

Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.

Cros J, Moati E, Raffenne J, Hentic O, Svrcek M, de Mestier L, Sbidian E, Guedj N, Bedossa P, Paradis V, Sauvanet A, Panis Y, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2016;103(5):495-9. doi: 10.1159/000440724. Epub 2015 Sep 4.

PMID:
26335532
49.

Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP.

Epigenetics. 2015;10(9):872-81. doi: 10.1080/15592294.2015.1076955.

50.

Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome.

Cauchy F, Mebarki M, Albuquerque M, Laouirem S, Rautou PE, Soubrane O, Raymond E, Bedossa P, Paradis V.

Gut. 2015 Sep;64(9):1498-500. doi: 10.1136/gutjnl-2015-310069. Epub 2015 Jun 29. No abstract available.

PMID:
26123027

Supplemental Content

Loading ...
Support Center